Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity
of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous
malignancies.